Carbamazepine Essential Pharma 125 mg Норвегія - норвезька - Statens legemiddelverk

carbamazepine essential pharma 125 mg

essential pharma (m) limited - karbamazepin - stikkpille - 125 mg

Carbamazepine Essential Pharma 250 mg Норвегія - норвезька - Statens legemiddelverk

carbamazepine essential pharma 250 mg

essential pharma (m) limited - karbamazepin - stikkpille - 250 mg

Iopidine 5 mg/ ml Норвегія - норвезька - Statens legemiddelverk

iopidine 5 mg/ ml

essential pharma limited - apraklonidinhydroklorid - Øyedråper, oppløsning - 5 mg/ ml

Miacalcic 100 IE/ ml Норвегія - норвезька - Statens legemiddelverk

miacalcic 100 ie/ ml

essential pharma (m) limited - laksekalsitonin - injeksjons-/infusjonsvæske, oppløsning - 100 ie/ ml

Haldol 1 mg Норвегія - норвезька - Statens legemiddelverk

haldol 1 mg

essential pharma limited - haloperidol - tablett - 1 mg

Haldol 5 mg/ ml Норвегія - норвезька - Statens legemiddelverk

haldol 5 mg/ ml

essential pharma limited - haloperidol - injeksjonsvæske, oppløsning - 5 mg/ ml

Haldol Depot 100 mg/ ml Норвегія - норвезька - Statens legemiddelverk

haldol depot 100 mg/ ml

essential pharma limited - haloperidoldekanoat - injeksjonsvæske, oppløsning - 100 mg/ ml

Celsunax Європейський Союз - норвезька - EMA (European Medicines Agency)

celsunax

pinax pharma gmbh - ioflupane (123i) - radionuclide imaging; dementia; movement disorders - diagnostiske radiopharmaceuticals - dette legemidlet er kun til diagnostisk bruk. celsunax is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy.  celsunax is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy. hos voksne pasienter, for å kunne skille mellom sannsynlig demens med lewy legemer fra alzheimers sykdom.  celsunax is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.

Anagrelide Mylan Європейський Союз - норвезька - EMA (European Medicines Agency)

anagrelide mylan

mylan pharmaceuticals limited - anagrelide hydrochloride - trombocytemi, essensielt - antineoplastiske midler - anagrelide er indikert for reduksjon av forhøyet platederivert teller i fare viktig thrombocythaemia (et) pasienter som er intolerante til deres nåværende terapi eller som har forhøyet platederivert teller ikke reduseres til et akseptabelt nivå ved deres nåværende terapi. an at-risk patientan at-risk essential thrombocythaemia patient is defined by one or more of the following features:>60 years of age ora platelet count >1,000 x 10⁹/l ora history of thrombo-haemorrhagic events.

Inrebic Європейський Союз - норвезька - EMA (European Medicines Agency)

inrebic

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastiske midler - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.